Compare Revvity Inc (RVTY) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Xpeng Inc - ADR — how do they compare? Revvity Inc trades at $154.1 (market cap $16.98B), while Xpeng Inc - ADR trades at $9.89 (market cap $9.16B). The key difference: Revvity Inc is the larger of the two by market cap, and Revvity Inc pays a 0.18% dividend while Xpeng Inc - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and Xpeng Inc - ADR for 80 Days on average.
| RVTY | XPEV | |
|---|---|---|
Market Cap | $16.98B | $9.16B |
Volume | 1,456,900 | 5,030,325 |
Sector | Health | Consumer Cyclical |
52-Week High | $157.36 | $28.07 |
52-Week Low | $82.26 | $9.25 |
Typical Hold Time | 12 Days | 80 Days |
Enterprise Value | $19.30B | $11.09B |
Dividend Yield | 0.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
XPeng (XPEV) trades at $9.90, up 3.34% with a bearish technical signal despite recent delivery growth. The company shows improving fundamentals with revenue surging to $76.72B in 2025 and narrowing losses, though it remains unprofitable with negative margins. Recent news highlights expansion into robotics and global vehicle launches, while analyst consensus remains bullish with a $17.55 price target representing 77% upside potential.
XPeng presents a high-risk, high-reward opportunity with strong revenue growth and technological innovation offset by persistent profitability challenges. The stock's current discount to analyst targets offers potential upside, but investors face risks from competitive pressures, execution challenges in new business lines, and ongoing losses that could pressure the balance sheet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
